Skip to main
GHRS

GHRS Stock Forecast & Price Target

GHRS Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GH Research is a clinical-stage biopharmaceutical company that is dedicated to improving the lives of patients with mental health disorders. Their focus on developing novel and proprietary treatments for Treatment-Resistant Depression, or TRD, shows a strong potential for success in a field with limited treatment options. With a completed enrollment in Phase 3 pivotal program and a strong pipeline portfolio, GH Research has demonstrated effective execution in moving their promising therapy forward.

Bears say

GH Research is facing several fundamental risks that could negatively impact its stock outlook. These include potential issues with FDA lifting the clinical hold on GH001, as well as the potential for the registrational Phase 3 study to not replicate the efficacy seen in earlier trials. Additionally, there are potential safety and tolerability concerns that could lead to the study being halted. Furthermore, there may be competition from other more efficacious products in the market, and the company may struggle to secure financing for the Phase 3 trial or for commercialization should GH001 be approved.

GHRS has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GH Research PLC (GHRS) Forecast

Analysts have given GHRS a Buy based on their latest research and market trends.

According to 7 analysts, GHRS has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GH Research PLC (GHRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.